FDA approves first gene therapy for Duchenne muscular dystrophy
The Food and Drug Administration June 22 approved the first gene therapy to treat patients aged 4-5 with a confirmed mutation in the Duchenne muscular dystrophy gene. As part of the drug’s accelerated approval, the drugmaker must conduct additional clinical trials to verify the predicted clinical benefit.
Related News Articles
Headline
Beth Heinz, senior vice president, Women’s and Children’s Services at Yale New Haven Health, and Cheri Johnson, chief nursing officer, Woman’s Hospital in…
Blog
One of our best strategies to address the unique behavioral health challenges and demands of pregnant women and new mothers is recognizing that mental health…
Headline
Rep. Robin Kelly, D-Ill., member of the Health Subcommittee of the Energy and Commerce Committee and chair of the Congressional Black Caucus Health Braintrust…
Headline
The American College of Obstetricians and Gynecologists April 17 released guidance recommending a new approach to prenatal care delivery. The guidance calls…
Headline
The National Institutes of Health April 7 released a study that found twins — smaller at birth on average than singletons — develop slower in early pregnancy…
Headline
A National Institutes of Health study published April 2 found that blood pressure patterns observed during the first half of pregnancy can determine a woman's…